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license (http://creativecommons.org/licenses/by-nc-nBackground: Reverse shoulder arthroplasty (RSA) has gained popularity in the treatment of proximal
humeral fractures (PHFs), especially in elderly patients. The purpose of this study was to investigate the
use of RSA implants for acute PHFs and risk of revision, as well as risk factors for revision.
Methods: RSA implants for acute PHFs were identified from the Nordic Arthroplasty Register Association
registry data from 2004 to 2016. Kaplan-Meier survival analysis was used to calculate implant survival.
Cox multiple regression analysis was used to calculate the adjusted revision rate for sex, age, country of
operation, and year of surgery.
Results: The study included 1523 RSA implants for PHFs (84% women; average age, 77 years; average
follow-up time, 2.5 years). The 5-year cumulative implant survival rate was 97% (confidence limits, 95.5%
and 98%). Revision was performed for 33 implants (2%). The most common reason for revision was
instability, occurring in 11 cases (0.7%), followed by fracture, occurring in 6 (0.4%), and infection,
occurring in 5 (0.3%). Four different arthroplasty brands were used in this cohort, with the Delta Xtend in
two-thirds of cases (n ¼ 1025). Age younger than 60 years and male sex were associated with slightly
higher rates of revision; however, these differences did not reach statistical significance (hazard ratio of
2.02 with P ¼ .075 and hazard ratio of 3.23 with P ¼ .057, respectively).
Conclusion: The use of RSA for acute PHFs is increasing in the Nordic countries. The short-term risk of
revision is low. The main reason for revision of RSA for this indication is instability.
© 2019 The Author(s). Published by Elsevier Inc. on behalf of American Shoulder and Elbow Surgeons.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Proximal humeral fractures (PHFs) comprise the third most classic alternative13 but is considered prone to complications and
common nonvertebral fracture type in the elderly population, after
hip and distal radial fractures.2,6 The majority of these fractures can
be treated nonoperatively.9 However, severely displaced fractures
in frail patients can pose a clinical problem, with various subopti-
mal surgical treatment options and an increased mortality rate.14 In
cases not amenable to osteosynthesis, hemiarthroplasty (HA) is thed for this retrospective case
artment of Orthopedics and
ty of Turku, Luolavuorentie 2,
€aki).
ier Inc. on behalf of American Sho
d/4.0/).revision procedures.11 Another, more recent alternative is the
reverse shoulder arthroplasty (RSA), which yields reportedly better
clinical results than HA,8,18 and consequently, RSA has gained
popularity in the treatment of PHFs.
All shoulder arthroplasties, including RSA, are associated with a
risk of complications that may require revision of the arthroplasty.
In the Australian shoulder register report from 2018, RSA for acute
PHFs had an average 5-year revision rate of 5%, and male patients
and patients younger than 75 years had an increased risk of revi-
sion.1 These findings are in accordance with those of a previous
Nordic Arthroplasty Register Association (NARA) report on RSA for
cuff tear arthropathy10 and for PHFs.4 However, the risk of revisionulder and Elbow Surgeons. This is an open access article under the CC BY-NC-ND
K. Lehtim€aki et al. / JSES International 4 (2020) 151e155152for RSA in the treatment of PHFs in the Nordic countries is not
known.
The purpose of this study was to evaluate the use of RSA for
acute PHFs and the risk of revision, as well as risk factors for revi-
sion, in the Nordic countries.
Materials and methods
Anonymous data collected by the national shoulder arthroplasty
registries in Denmark, Norway, Sweden, and Finland from 2004-
2016 were merged into a combined data set under the umbrella of
the NARA. The data set includes information on patient de-
mographic characteristics (age, sex, and diagnosis), as well as the
primary operation (operation date, arthroplasty type, and implant
brand), and in the case of revision, the date of and reason for
revision. If more than 1 diagnosis or reason for revision is reported,
a hierarchy is used so that only the single most important diagnosis
or reason for revision is registered.17 Fracture sequelae were
defined as fractures reported as nonunion or malunion with pre-
vious osteosynthesis or together with osteoarthritis or humeral
head necrosis, and acute fractures were defined as all fractures that
were not categorized as fracture sequelae, regardless of time from
injury to operation. Data on cases with RSA and acute fracture were
identified and extracted for analyses.
Descriptive statistics were used to report the demographic data,
use of RSA, and reasons for revision. The Kaplan-Meier method was
used to estimate the unadjusted cumulative survival rate, and the
log-rank test was used for comparison. Cox multiple regression
analysis was used to calculate the adjusted hazard ratio (HR) for
revision for sex, age group (<60, 60-75, and >75 years), country of
operation, and year of surgery (2004-2009, 2010-2013, and 2014-
2016). Statistical analysis was performed using SAS software
(version 9.3; SAS Institute, Cary, NC, USA). The level of statistical
significance was set at P < .05, and all P values were 2-tailed.Figure 1 Number of reverse shoulder arthroplasties for proximaResults
A total of 8938 RSAs were registered; of these, 1523 were RSAs
for acute PHFs. There were 1282 female patients (84%) and 241
male patients (16%). The average age was 77 years (standard de-
viation, 8.5 years; range, 49-89 years), and the average follow-up
time was 2.5 years (range, 0-11.6 years). The yearly number of
arthroplasties increased throughout the study period (Fig. 1). There
were 33 revisions (2%), with the most common reason for revision
being instability, occurring in 11 cases (0.7%). Fracture and infection
were reasons for revision in 6 cases (0.4%) and 5 cases (0.3%),
respectively (Fig. 2). The overall 5-year cumulative survival ratewas
97% (confidence limits, 95.5% and 98%) (Fig. 3). The most common
arthroplasty brand used in this cohort was the Delta Xtend (DePuy
Synthes, Warsaw, IN, USA), constituting two-thirds of the implants
(n ¼ 1025). The comparative survival analysis is presented with the
4 most common brands, comprising the Delta Xtend, Aequalis
reverse (Wright Medical, Memphis, TN, USA) (n ¼ 182), Biomet
Comprehensive reverse (Biomet, Warsaw, IN, USA) (n ¼ 89), and
Lima SMR Reverse Shoulder Prosthesis (Lima Corporate, Udine,
Italy) (n ¼ 75) (Fig. 4). The HR for revision of each brand compared
with the Delta Xtend was 1.33 (P ¼ .720), 4.36 (P ¼ .030), and 13.11
(P < .001), respectively. Patient age younger than 60 years andmale
sex were associated with slightly higher risks of revision; however,
the difference did not reach statistical significance (HR of 2.02 with
P ¼ .075 and HR of 3.23 with P ¼ .057, respectively). Year and
country of surgery were not statistically significantly associated
with the risk of revision. The mortality rate within 1 year after the
operation was 4.3%, with a total of 243 deaths in the cohort.
Discussion
The main finding of our study is the increased utilization of RSA
for acute PHFs in the Nordic countries, especially for the treatmentl humeral fracture in Nordic countries during study period.
Figure 2 Reason and time of revision (in years) after reverse shoulder arthroplasty for proximal humeral fracture.
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increasing general trends of surgical treatment for this type of
fracture7 and use of RSA for this indication.1,12 This may be
explained by the increase in the aging population and a subsequent
increase in low-energy fractures,5 as well as by a marked change in
surgeon behavior regarding the advocated treatment.
The leading cause of revision of RSA in our cohort was insta-
bility, followed by fracture and infection. Instability may be related
to the initial fracture, suboptimal positioning of the RSA implant, or
inferior stability due to a tear of the subscapularis tendon or lack of
healing of the tuberosities. Most of these revisions occurred early,
within 1 year after surgery, and thereafter, revisions were less
frequent. This finding is in accordance with the results of previousFigure 3 Cumulative survival of reverse shoulderreports by Dillon et al7 and Noguera et al.15 Despite the low overall
number of fractures that led to revision of RSA in our cohort, the
incidence was higher than in reports on RSA for cuff tear arthrop-
athy.10 Unfortunately, we have no detailed data on the type of
periprosthetic fractures and no information about periprosthetic
fractures that did not require revision with exchange or removal of
the RSA implant. A PHF and concomitant soft-tissue contusion may
theoretically predispose to infection; however, the risk of revision
for infection was low in our cohort.
The Delta Xtend was used in a high number of cases and had a
low revision rate. The apparent routine use of 1 predominant brand
in the Nordic region makes it difficult to compare with other
brands. The possibility to detect a difference in survival betweenarthroplasty for proximal humeral fracture.
Figure 4 Survival of 4 most common reverse shoulder arthroplasty brands for proximal humeral fracture.
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However, in the report using Australian register data, the risk of
revision is similar to our findings, with the SMR prosthesis having
the highest risk of revision compared with other brands.1
The risk of revision was not statistically significantly associated
with any of the analyzed patient parameters. Contrary to previous
reports, risks related to male sex and young age were not statisti-
cally significant in our cohort.16 This finding may be partly
explained by the relatively small number of male and young pa-
tients, as well as low statistical power. Therefore, these results
should be interpreted with caution. A comminuted PHF is charac-
teristic for old frail female patients with an increasedmortality rate.
The 1-year mortality rate was 4% in our cohort. Previously, an even
higher rate of 10% has been reported for PHF patients, independent
of the treatment algorithm.8 This difference may represent a po-
tential selection of healthier patients for RSA surgery in our cohort.
No consensus exists on treatment strategies for PHFs. However,
a recently published treatment algorithm has suggested, without
high-level comparative evidence, the use of RSA in comminuted
fractures in elderly patients with osteoporotic bone.19 RSA has been
reported to have superior results compared with HA at 5 years
postoperatively, with a comparable, low revision rate.3 However,
the lack of detailed information and missing clinical outcome data
are major limitations in our study. It may be that some revisions
yield good clinical outcomes and, on the other hand, not all clinical
failures undergo revision. The accuracy and completeness of reg-
istry data may also be questioned; however, 80%-90% of all
arthroplasties are reported in the NARA registry, within our
condensed minimal data set. Therefore, our report indeed reflects
the clinical practice in the Nordic countries.
Conclusion
RSA as treatment for PHFs is increasing in the Nordic region. The
short-term risk of revision is low. On the basis of implant survival,RSA is an applicable treatment option for PHFs. Further research is
required to evaluate the comparative clinical outcomes of different
modalities in the treatment of PHFs.
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